Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole

Chembiochem. 2009 Jul 6;10(10):1634-9. doi: 10.1002/cbic.200900192.

Abstract

Combinatorial biosynthesis meets combinatorial pharmacology, cyanobacterial style: A new antimitotic natural product with features of both dolastatins 10 and 15 was isolated from the same Floridian Symploca sp. sample that produced the histone deacetylase inhibitor largazole. Both agents in combination are more effective in inhibiting cancer cell proliferation than either agent alone.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antimicrobial Cationic Peptides
  • Antimitotic Agents / chemistry*
  • Antimitotic Agents / pharmacology
  • Antimitotic Agents / toxicity
  • Antineoplastic Combined Chemotherapy Protocols / chemistry*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Cell Cycle
  • Cell Line, Tumor
  • Cyanobacteria / chemistry*
  • Depsipeptides / chemistry
  • Depsipeptides / pharmacology*
  • Histone Deacetylase Inhibitors*
  • Histone Deacetylases / metabolism
  • Humans
  • Peptides / chemistry*
  • Peptides / pharmacology
  • Thiazoles / chemistry
  • Thiazoles / pharmacology*

Substances

  • Antimicrobial Cationic Peptides
  • Antimitotic Agents
  • Depsipeptides
  • Histone Deacetylase Inhibitors
  • Peptides
  • Thiazoles
  • gallinamide A
  • largazole
  • dolastatin 15
  • Histone Deacetylases
  • dolastatin 10